Cancer upregulated gene 2 induces epithelial-mesenchymal transition of human lung cancer cells via TGF-β signaling

被引:35
|
作者
Kaowinn, Sirichat [1 ]
Kim, Jeonghyo [1 ]
Lee, Jaebeom [1 ]
Shin, Dong Hoon [2 ]
Kang, Chi-Dug [3 ]
Kim, Dae-Kee [4 ]
Lee, Soojin [5 ]
Kang, Min Kyung [6 ]
Koh, Sang Seok [6 ]
Kim, Seong-Jin [7 ,8 ]
Chung, Young-Hwa [1 ]
机构
[1] Pusan Natl Univ, Dept Cognomechatron Engn, BK21, Busan 609735, South Korea
[2] Pusan Natl Univ, Sch Med, Dept Pathol, Yangsan 626870, South Korea
[3] Pusan Natl Univ, Sch Med, Dept Biochem, Yangsan 626870, South Korea
[4] Ewha Womans Univ, Grad Sch Pharmaceut Sci, Coll Pharm, Seoul 120750, South Korea
[5] Chungnam Natl Univ, Dept Microbiol & Mol Biol, Daejeon 305764, South Korea
[6] Dong A Univ, Dept Biol Sci, Busan 604714, South Korea
[7] CHA Univ, CHA Canc Inst, Seoul 135081, South Korea
[8] CHA Univ, Dept Biomed Sci, Seoul 135081, South Korea
基金
新加坡国家研究基金会;
关键词
CUG2; TGF-beta; EMT; Sp1; Smad2/3; TRANSCRIPTION FACTOR SP1; PRIMARY BREAST-CANCER; CENTROMERE-PROTEIN-H; TRANSFORMING GROWTH-FACTOR-BETA-1; COLORECTAL-CANCER; CENP-W; EXPRESSION; ONCOGENE; OVEREXPRESSION; NUCLEOPHOSMIN;
D O I
10.18632/oncotarget.13867
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer upregulated gene 2 (CUG2) enhances cell migration and invasion, but the underlying mechanism has not been revealed. Herein, CUG2 decreased the expression of E-cadherin and increased the expression of N-cadherin and vimentin, characteristics of the epithelial-mesenchymal transition (EMT). A CUG2 deletion mutant, lacking interaction with nucleophosmin 1 (NPM1), or suppression of NPM1 reduced wound healing and cell invasion, indicating that CUG2-mediated EMT requires NPM1. CUG2 enhanced activation of Smad2/3 and expression of Snail and Twist, while the CUG2 silence decreased these TGF-beta signaling pathways, leading to suppression of EMT. NPM silence also inhibited the CUG2-induced TGF-beta signaling. These results suggest that TGF-beta signaling is involved in CUG2-induced EMT. Treatment with EW-7197, a novel inhibitor of TGF-beta signaling, diminished CUG2-mediated EMT and inhibition of Akt, ERK, JNK, and p38 MAPK, non-canonical TGF-beta signaling molecules, also decreased expression of Smad2/3, Snail and Twist, leading to inhibition of EMT. The results confirm that TGF-beta signaling is essential for CUG2-mediated EMT. Interestingly, TGF-beta enhanced CUG2 expression. We further found that both CUG2-induced TGF-beta production and TGF-beta-induced CUG2 up-regulation required a physical interaction between Sp1 and Smad2/3 in the CUG2 and TGF-beta promoter, as demonstrated by a promoter reporter assay, immunoprecipitation, and ChIP assay. These results indicated close crosstalk between CUG2 and TGF-beta. Conversely, suppression of CUG2 or NPM1 did not completely inhibit TGF-beta-induced EMT, indicating that the effect of TGF-beta on EMT is dominant over the effect of CUG2 on EMT. Collectively, our findings suggest that CUG2 induces the EMT via TGF-beta signaling.
引用
收藏
页码:5092 / 5110
页数:19
相关论文
共 50 条
  • [41] Hispolon as an inhibitor of TGF-β-induced epithelial-mesenchymal transition in human epithelial cancer cells by co-regulation of TGF-β-Snail/Twist axis
    Hong, Darong
    Park, Min-Ju
    Jang, Eun Hyang
    Jung, Bom
    Kim, Nam-Jung
    Kim, Jong-Ho
    ONCOLOGY LETTERS, 2017, 14 (04) : 4866 - 4872
  • [42] p68 prompts the epithelial-mesenchymal transition in cervical cancer cells by transcriptionally activating the TGF-β1 signaling pathway
    Li, Ming-Yi
    Liu, Jin-Quan
    Chen, Dong-Ping
    Li, Zhou-Yu
    Qi, Bin
    Yin, Wen-Jing
    He, Lu
    ONCOLOGY LETTERS, 2018, 15 (02) : 2111 - 2116
  • [43] Blocking TGF-β expression inhibits silica particle-induced epithelial-mesenchymal transition in human lung epithelial cells
    Rong, Yi
    Shen, Yan
    Zhang, Zhihong
    Cui, Xiuqing
    Xiao, Lili
    Liu, Yuewei
    Luo, Xin
    Chen, Weihong
    ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 2015, 40 (03) : 861 - 869
  • [44] TGF-β-induced epithelial-mesenchymal transition: A link between cancer and inflammation
    Fuxe, Jonas
    Karlsson, Mikael C. I.
    SEMINARS IN CANCER BIOLOGY, 2012, 22 (5-6) : 455 - 461
  • [45] TGFβ Induces Epithelial-Mesenchymal Transition of Thyroid Cancer Cells by Both the BRAF/MEK/ERK and Src/FAK Pathways
    Baquero, Pablo
    Jimenez-Mora, Eva
    Santos, Adrian
    Lasa, Marina
    Chiloeches, Antonio
    MOLECULAR CARCINOGENESIS, 2016, 55 (11) : 1639 - 1654
  • [46] Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling
    Wang, Zi-li
    Fan, Zhi-qiang
    Jiang, Han-dong
    Qu, Jie-ming
    CARCINOGENESIS, 2013, 34 (03) : 638 - 646
  • [47] Mummy Induces Apoptosis Through Inhibiting of Epithelial-Mesenchymal Transition (EMT) in Human Breast Cancer Cells
    Barouji, Solmaz Rahmani
    Shahabi, Arman
    Torbati, Mohammadali
    Fazljou, Seyyed Mohammad Bagher
    Khosroushahi, Ahmad Yari
    GALEN MEDICAL JOURNAL, 2020, 9
  • [48] Menin Coordinates C/EBPβ-Mediated TGF-β Signaling for Epithelial-Mesenchymal Transition and Growth Inhibition in Pancreatic Cancer
    Cheng, Peng
    Chen, Ying
    He, Tian-lin
    Wang, Chao
    Guo, Shi-wei
    Hu, Hao
    Ni, Chen-ming
    Jin, Gang
    Zhang, Yi-jie
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2019, 18 : 155 - 165
  • [49] DcR3 induces epithelial-mesenchymal transition through activation of the TGF-β3/SMAD signaling pathway in CRC
    Liu, Yan-Ping
    Zhu, Hui-Fang
    Liu, Ding-Li
    Hu, Zhi-Yan
    Li, Sheng-Nan
    Kan, He-Ping
    Wang, Xiao-Yan
    Li, Zu-Guo
    ONCOTARGET, 2016, 7 (47) : 77306 - 77318
  • [50] Tranilast Inhibits TGF-β1-induced Epithelial-mesenchymal Transition and Invasion/Metastasis via the Suppression of Smad4 in Human Lung Cancer Cell Lines
    Takahashi, Koji
    Menju, Toshi
    Nishikawa, Shigeto
    Miyata, Ryo
    Tanaka, Satona
    Yutaka, Yojiro
    Yamada, Yoshito
    Nakajima, Daisuke
    Hamaji, Masatsugu
    Ohsumi, Akihiro
    Chen-Yoshikawa, Toyofumi Fengshi
    Sato, Toshihiko
    Sonobe, Makoto
    Date, Hiroshi
    ANTICANCER RESEARCH, 2020, 40 (06) : 3287 - 3296